What You Should Know:
– BrightInsight, provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced a partnership with global biopharma, UC to build digital care solutions for rare diseases.
– BrightInsight will build and bring to market a digital disease management solution to support patients with Myasthenia Gravis (MG), a rare autoimmune disease that disrupts how nerves communicate with muscles, affecting more than 700,000 people worldwide and approximately 36,000 to 60,000 in the United States.
BrightInsight, Inc., a provider of the leading global platform for biopharma and medtech regulated digital health solutions, today announced a partnership with the global biopharmaceutical company, UCB, to develop and bring to market a digital disease management solution for patients with rare diseases. UCB selected the proven, scalable Brightinsight® Platform to accelerate time to market for UCB’s digital care solutions in a compliant manner.
UCB’s Digital Care Solutions for Myasthenia Gravis
Built under a robust Quality Management System to support regulated products, the BrightInsight Platform enables UCB to develop and launch its digital health solutions at scale while maintaining compliance with privacy, security, and regulatory requirements across the globe. Leveraging the BrightInsight Platform, built on Google Cloud, UCB’s digital disease management solution will first include a mobile patient app to support patients with Myasthenia Gravis (MG), a rare autoimmune disease that disrupts how nerves communicate with muscles. The solution and its future evolution will help those living with MG better manage their condition and supports UCB’s commitment to bringing digital solutions to patients with rare diseases to improve overall care and outcomes. The solution will be available first in the U.S., with plans to incorporate feedback and patient insights into future versions, to eventually launch on a global scale.
Why Digital for Rare Diseases?
Patients and providers face several challenges managing rare diseases that make it a promising field for digital solutions. Because rare diseases can be difficult to diagnose and often require multiple referrals to specialists, patients can go years waiting for a diagnosis. That can cause a lack of trust in medical providers and lower adherence. Powerful algorithms hosted on a digital platform can help patients get diagnosed faster and on the right treatment earlier.
Digital solutions can help support a patient’s treatment journey with apps and other digital tools, including medication reminders and tracking tools, information on disease management, patient journals, and a secure line of communication with their healthcare providers to enable real-time information sharing to optimize care. For patients in remote areas, these tools can help them connect with specialty care from the comfort of home.
A systematic review of digital interventions for one rare disease found that 94% of participants reported improvement in self-management-related outcomes. And 63% showed high levels of satisfaction and acceptability of the interventions.
UCB is the third pharma to partner with BrightInsight in rare diseases. The others BrightInsight partnerships include Roche/Genentech who developed a dosing calculator for physicians treating patients with Hemophilia A and with CSL Behring who built a patient app for its flagship drug, Hizentra® for Primary Immune Deficiency (PID) or for Chronic lnflammatory Demyelinating Polyneuropathy (CIDP).
“BrightInsight welcomes UCB to our growing list of innovative, global biopharma partners who are prioritizing digital health and who rely on our proven platform to bring compliant digital solutions to market,” said Kal Patel, M.D., CEO & Co-Founder, BrightInsight. “We are pleased to be UCB’s digital health partner and to collaborate with them to bring digital solutions to patients with rare diseases. Our collaboration reflects our companies’ common goal to develop digital health solutions for disease management that enable better patient experiences and outcomes.”
